19.05.2011 • NewsGen-ProbeThermo FisherNovartis

Bidders Emerge For Gen-Probe, Phadia

Bidders emerged for allergy-testing company Phadia and diagnostic test-maker Gen-Probe, according to The Wall Street Journal.

Laboratory equipment company Thermo Fisher Scientific is a leading contender for privately owned Phadia, and is involved in the auction for Gen-Probe, the newspaper reported in its online edition.

Phadia could fetch as much as $3 billion in a sale, while Gen-Probe has a market capitalization of $3.8 billion.

Other bidders for Gen-Probe include Novartis, and Life Technologies Corp, the newspaper said.

Gen-Probe, Phadia, Thermo Fisher declined to comment. Life Technologies and Novartis, which has a partnership with Gen-Probe, could not be immediately reached for comment.

Last month, Gen-Probe hired Morgan Stanley to seek a buyer for the company, sources familiar with the situation said.

 

 

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.